Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, hosted a Key Opinion Leader (KOL) call on why exosomes are uniquely suited for vaccine development on March 26, 2020.
Tagged with: Capricor Therapeutics
Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy Volunteers
17 days ago
26 days ago